Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04068467 · ClinicalTrials.gov registry record · NA

Evaluation of mHealth for Serious Mental Illness

A NA study, sponsored by University of Washington.

Completed
Registry status
NA
Development phase
315
Enrollment target

NCT04068467: Completed NA study, sponsored by University of Washington.

NCT04068467 is a NA study that has completed, run by University of Washington. The registered enrollment target is 315 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04068467, a NA study, has completed, sponsored by University of Washington.

COMPLETED
Registry status
NA
Development phase
315 participants
Enrollment target

Study Summary

This study is a waitlist control trial evaluating the acceptability and preliminary efficacy of a smartphone application with people with mental illness.

Primary Outcome

The Beck Depression Inventory is a self-reported 21-item inventory, scores range from 0-63 and items are summed to compute the total score. A higher score represents more depressive symptoms.

Interventions

  • OTHER Waitlist Control
  • OTHER Smartphone App

Trial Details

FieldValue
Enrollment Target 315 participants
Start Date 2020-01-06
Est. Completion 2021-05-01
Phase NA
University of Washington

1,048 total trials

What the finished NCT04068467 record still lists

NCT04068467 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 2 interventions - of which Waitlist Control is the first listed.

NCT04068467 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04068467 about?

NCT04068467 is a clinical study titled "Evaluation of mHealth for Serious Mental Illness". This study is a waitlist control trial evaluating the acceptability and preliminary efficacy of a smartphone application with people with mental illness.

What is the current status of trial NCT04068467?

This trial is currently completed. It is a NA study. The enrollment target is 315 participants. The study started on 2020-01-06. Estimated completion is 2021-05-01.

What interventions are being tested in trial NCT04068467?

The interventions under investigation include: Waitlist Control (OTHER), Smartphone App (OTHER).

Who is sponsoring clinical trial NCT04068467?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04068467's enrollment target sits among peer trials

315 323rd of 2000 higher than 1,678 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04812366 · 315 participants · Phase 2

    Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

  • NCT05101460 · 315 participants

    An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant

  • NCT05897320 · 315 participants · Phase 3

    A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

  • NCT06439082 · 315 participants · Phase 3

    A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04068467, the US trial registry maintained by the National Library of Medicine. NCT04068467 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.